Genomic Medicine Alliance News
- Tuesday, 03 May 2016
The Genomic Medicine Alliance proudly announces the formation of the DRIFT Consortium with Regeneron Genetics Center (RGC). The DRIFT (Discovery Research Investigating Founder Population Traits) Consortium is an open call for research collaboration to understand the genetic architecture of founder populations throughout the world to impact health and disease.
With this agreement, academic institutions and research centers from developing countries and resource-limited environments will be given a unique opportunity to engage into advanced genomics research to elucidate the underlying genetic etiology of rare diseases in their population FREE-OF-CHARGE.
DRIFT is planning two tiers of collaboration models (see details below). For both models, we intend to broadly share data and results with the research community. If exciting new results are generated from a Tier 1 or Tier 2 collaboration, there will be potential for the design and funding of follow-up “genotype-first call-back” studies for additional collaborative research to delve more deeply into biological mechanisms and pathways. Participating academic institutions and research centers from developing countries will provide the RGC de-identified DNA samples with (Tier-2) or without (Tier-1) phenotypic information. RGC will provide these centers whole exome sequencing and genome-wide association (with phenotype, where applicable) data free-of-charge. Data analyses of the combined genotype-phenotype data (where applicable) will be performed collaboratively and each party will be free to: (i) use these datasets for its internal research; (ii) publish results; (iii) use published results for any and all purposes.
For further inquiries and information for participation, please contact:
Click here to read the full announcement published in Public Health Genomics, the Official journal of the Genomic Medicine Alliance
- Thursday, 14 April 2016
The Genomic Medicine Alliance proudly announces the organization of the 2016 Golden Helix Summer School in the island of Syros, Greece, September 22-26, 2016. The theme of the meeting will be "Cancer Genomics and Individualized Therapy" and will include plenary lectures by over 24 local and international speakers coming from Europe and the United States.
The 2016 Golden Helix Summer School will also include a Science night that will be open to the public, where local speakers will give state-of-the-art lectures on recent developments on cancer treatment and prevention. As with the previous event, the 2016 Golden Helix Summer School will feature a career development sessions, flash talks of the best abstracts, and interactive and poster sessions.
ALL abstracts submitted for presentation at the 2016 Golden Helix Summer School will be published in a Supplementary issue of Public Health Genomics, the official journal of the Genomic Medicine Alliance.
Please visit the 2016 Golden Helix Summer School website to access the scientific program and to register for the event.
Workshop: 16th Golden Helix Pharmacogenomics Day at Festival of Genomics Boston in June 22nd 2015, 16:00-19:00
- Friday, 08 May 2015
The 16th Golden Helix Pharmacogenomics Day is an educational event that aims to provide timely updates on the field of pharmacogenomics and personalized medicine to the local biomedical scientists and healthcare providers, to inform them on the application of pharmacogenomics in fields such as psychiatric disorders, oncology, and to bring together faculty members from universities and research institutes from the local scientific arena working in the field of pharmacogenomics in order to initiate collaborative projects in this field to the benefit of society.
This workshop will include:
- Lectures by 6 speakers from the US, both from academia, industry and regulatory (NIH) backgrounds.
- Topics will pertain to pharmacogenomics and personalized medicine
- The Global Genomic Medicine Collaborative and the Genomic Medicine Alliance initiatives will be highlighted.
What will participants take away from this workshop?
- The most recent trends on pharmacogenomics
- The aims and goals of the Global Genomic Medicine Collaborative and the Genomic Medicine Alliance Initiatives
- Collaboration and training opportunities with the faculty of the workshop
George P. Patrinos, University of Patras Department of Pharmacy, Patras, Greece
Konstantinos Mitropoulos, the Golden Helix Foundation, London, UK
- Teri Manolio, Director, Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
- Federico Innocenti, Associate Professor, University of North Carolina, Chapel Hill, NC, USA
- Alan R. Shuldiner, Vice President, Translational Genetics, Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
- Marc S. Williams, Director, Genomic Medicine Institute, Geisinger Health System, Danville, PA,USA
- George P. Patrinos, Associate Professor, University of Patras Department of Pharmacy, Patras, Greece
- Deepak Voora, Assistant Professor, Duke Center for Genomic and Computational Biology, Durham, NC, USA
Enter promo code: Helix25 and get 25% off at registration.
- Thursday, 19 February 2015
The Genomic Medicine Alliance has joined this week, as Organizational member, the Global Alliance for Genomics and Health.
The Global Alliance for Genomics and Health aims to help accelerate the potential of genomic medicine to advance human health.The Global Alliance works to establish, broadly disseminate, and advocate for the use of interoperable technical standards for managing and sharing genomic and clinical data. At present, the Global Alliance brings together over 220 leading institutions working in healthcare, research, disease advocacy, life science, and information technology that are working together to create a common framework of harmonized approaches to enable the responsible, voluntary, and secure sharing of genomic and clinical data.
By partnering with the Global Alliance, the Genomic Medicine Alliance aims to create synergies for the benefit of its members, particularly from developing countries, where genomics data sharing is still in its infancy.